Jared Baeten | Vice President, HIV Clinical Development
Gilead Sciences

Jared Baeten, Vice President, HIV Clinical Development, Gilead Sciences

Jared Baeten, MD, PhD is Vice President of Clinical Development at Gilead Sciences, leading the company's strategy for HIV Treatment, Prevention, and Cure.

Jared has conducted extensive research over the past two decades focusing on the prevention of HIV globally, including clinical trials, large-scale epidemiologic studies, and behavioral and implementation science research. He led the Partners PrEP Study, which supported the approval of Truvada as pre-exposure prophylaxis (PrEP) for HIV prevention in 2012 and a second trial that led to the first approval of a topical microbicide for HIV prevention. He has published over 400 scientific articles related to HIV and has extensive expertise related to the development of next-generation researchers around the world. His work is driven by a strong sense of justice, equity, and dedication to ending the global epidemic.

Jared served as Director of the University of Washington/Fred Hutch Center for AIDS Research, Co-Principal Investigator of the NIH-funded Microbicides Trials Network, and Professor of Global Health, Medicine and Epidemiology at the University of Washington, where he was the Vice Dean for Strategy, Faculty Affairs and New Initiatives at the School of Public Health. He is a Fellow of the Infectious Diseases Society of America and an elected member of the American Society for Clinical Investigation.


WVIC/WAC Day 1 - Nov 29 @ 09:00

Panel: HIV – how can we end the epidemic?

  • How is new research bringing the goal of a cure within reach? 

  • HIV Vaccine, antibody, and antiviral landscape

  • Merits / potential of different approaches – mRNA, bNAbs, LAAV, pre-exposure prophylaxis, prophylactic vs therapeutic vaccines 

    o How are we defining functional cure? 

    o Is the benchmark for a vaccine too high given the effectiveness of LAAV regimen?

  • To achieve success must reach all those disproportionately affected - How can PPP help to achieve this? 

WVIC/WAC Day 1 - Nov 29 @ 16:50

Are long-acting ARTs the future of HIV prevention and treatment?

  • How can we improve the half-life of long-acting ARTs?
  • How can we enhance the uptake/usage of long-acting formulations?
  • What are the implementation challenges for therapies?
  • What are the key policy issues for these types of therapies?
  • Why can long-acting injectable therapies be difficult to access in LMIC?
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard


For sponsorship and exhibition opportunities:
Thomas Hall